































# Pharmaceuticals —

## Pipeline Overview and Progress






April 29, 2026 –  
Investor Relations



# Pharmaceuticals – Pipeline Overview<sup>1</sup> (as of April 29, 2026)

Phase I	Phase II	Phase III
<b>VVD KEAP1 Act</b> (VVD-130037 aka <i>NRF2 Inh</i> , BAY 3605349)  ●	<b>Sevabertinib</b> (HER2/mEGFR Inhibitor) (BAY 2927088)  ○	<b>Darolutamide</b> (AR Inhibitor)  ○
<b>Actinium (225Ac) Pelgifatamab Mopaxetan</b> (BAY 3546828)  ●	<b>Umiposgene Parvec</b> (AAV Gene Therapy) (AB-1002)  ●	<b>Sevabertinib</b> (HER2/mEGFR Inhibitor)  ○
<b>Actinium (225Ac) Felivotide Mopaxetan</b> (BAY 3563254)  ●	<b>Inclocibart</b> (anti-a2AP) (BAY 3018250)  ●	<b>Finerenone</b> (MR Antagonist)  ○
<b>SOS1 Inhibitor</b> (BAY 3498264)  ●	<b>Nurandociguat</b> (sGC Activator Oral) (BAY 3283142)  ●	<b>Bemdaneprocel</b> (Cell Therapy)  ●
<b>PRMT5 Inhibitor</b> (BAY 3713372)  ●	<b>SEMA 3a Inhibitor</b> (BAY 3401016)  ●	<b>Mirena</b> (Levonorgestrel-releasing Intrauterine System)  ○
<b>VVD RAS-PI3K Inhibitor</b> (VVD-159642, BAY 3674171)  ●	<b>Ametefgene Parvec</b> (AAV Gene Therapy) (AB-1005)  ●	<b>124I-Evuzamitide</b> (PET Tracer)  ●
<b>225Ac-GPC3</b> (BAY 3547926)  ●		
<b>VVD WRN Inhibitor</b> (VVD-214)  ●		
<b>KRAS G12D Inhibitor</b> (BAY 3771249)  ●		
<b>Dual FIIa/Xa Inhibitor</b> (BAY 3389934)  ●		
<b>GIRK4 Inhibitor</b> (BAY 3670549) ●		
<b>BAY 3620122</b>  ●		
<b>Ametefgene Parvec</b> (AAV Gene Therapy) (AB-1005)  ●		
<b>Multiple System Atrophy</b>		
<b>Pompe Disease AAV Gene Therapy</b> (AB-1009 aka <i>PROGRESS-GT LOPD</i> )  ●		
<b>LGMD2I/R9 AAV Gene Therapy</b> (AB-1003 aka <i>LION-101</i> )  ●		
<b>Primary Photoreceptor Diseases Cell Therapy</b> (BRT-OpCT-001)  ●		
<b>AT-05 SPECT Tracer</b>  ●		

 Protein Therapy 
  Cell Therapy 
  Genetic Therapy 
  Radionuclide Therapy 
  Imaging Agent 
  Small Molecule

Submissions
<b>Sevabertinib</b> (HER2/mEGFR Inhibitor)  ●
# CN, JP: HER2-mut NSCLC 2L
<b>Finerenone</b> (MR Antagonist)  ○
# CN: Heart Failure (HFmr/pEF)
# US: Chronic Kidney Disease in Type 1 Diabetes
<b>Asundexian</b> (FXIa Inhibitor)  ●
# CN: 2 <sup>o</sup> Stroke Prevention
<b>Aflibercept 8mg</b> (VEGF-Inhibitor)  ○
# CN: Retinal Vein Occlusion
<b>Gadoquatrane</b> (High Relaxivity Contrast Agent)  ●
# US, EU, CN: Magnetic Resonance Imaging

- Oncology
- Cardiovascular & Renal
- Neurology & Rare Diseases
- Immunology
- Others
- New Molecular Entity
- Indication Expansion

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit



# Pharmaceuticals – Pipeline Details Oncology<sup>1</sup>

(as of April 29, 2026)

Candidate medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
Darolutamide (AR Inhibitor)	Adjuvant Prostate Cancer (DASL-HiCaP)					<a href="#">NCT04136353</a>	Q1 2028	Study ongoing
	Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASSTEP)					<a href="#">NCT05794906</a>	Q3 2027	Study ongoing
Sevabertinib (HER2/mEGFR Inhibitor) (BAY 2927088)	Advanced Non-small Cell Lung Cancer with HER2 Activating Mutations, 1L (SOHO-02)					<a href="#">NCT06452277</a>	Q4 2027	Study ongoing
	Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)					<a href="#">NCT06760819</a>	Q1 2027	Study ongoing
VVD KEAP1 Act (VVD-130037 aka NRF2 Inh, BAY 3605349)	Advanced Solid Tumors					<a href="#">NCT05954312</a>	Q3 2030	Study ongoing
Actinium (225Ac) Pelgifatamab Mopaxetan (BAY 3546828)	Advanced Prostate Cancer					<a href="#">NCT06052306</a>	Q2 2027	Study ongoing
Actinium (225Ac) Felivotide Mopaxetan (BAY 3563254)	Advanced Prostate Cancer					<a href="#">NCT06217822</a>	Q4 2028	Study ongoing
SOS1 Inhibitor (BAY 3498264)	Advanced Solid Cancers					<a href="#">NCT06659341</a>	Q3 2027	Study ongoing
PRMT5 Inhibitor (BAY 3713372)	MTAP-deleted Solid Tumors					<a href="#">NCT06914128</a>	Q2 2029	Study ongoing
VVD RAS-PI3K Inhibitor (VVD-159642, BAY 3674171)	Advanced Solid Tumors					<a href="#">NCT06804824</a>	Q3 2027	Study ongoing
225Ac-GPC3 (BAY 3547926)	Advanced Liver Cancer					<a href="#">NCT06764316</a>	Q3 2029	Study ongoing
VVD WRN Inhibitor (VVD-214)	Advanced Solid Tumors					<a href="#">NCT06004245</a>	Q2 2027	Study ongoing
KRAS G12D Inhibitor (BAY 3771249)	Advanced Solid Tumors					<a href="#">NCT07207707</a>	Q3 2026	Study ongoing

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit
















<sup>3</sup> \*Bayer acquired Noria and PSMA Therapeutics in 2021

/// Bayer Pharmaceuticals /// Pipeline Overview April 29, 2026



# Pharmaceuticals – Pipeline Details Cardiovascular & Renal<sup>1</sup>

(as of April 29, 2026)

Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
<b>Finerenone</b> (MR Antagonist)	<b>Non-diabetic CKD</b> ( <i>FIND-CKD</i> )					<a href="#">NCT05047263</a>	Q4 2025	Study completed
<b>Umiposgene Parvec</b> (AAV Gene Therapy) ( <i>AB-1002</i> )	<b>Congestive Heart Failure</b> ( <i>GenePHIT</i> )					<a href="#">NCT05598333</a>	Q4 2026	Study ongoing
<b>Inclocibart</b> (anti-a2AP) ( <i>BAY 3018250</i> )	<b>Acute Ischemic Stroke; Pulmonary Embolism</b> ( <i>SIRIUS</i> )					<a href="#">NCT06149520</a>	Q4 2025	Study completed
<b>Nurandociguat</b> (sGC Act. Oral) ( <i>BAY 3283142</i> )	<b>Chronic Kidney Disease (CKD)</b> ( <i>ALPINE 1</i> )					<a href="#">NCT06522997</a>	Q4 2025	Study completed
<b>SEMA 3a</b> ( <i>BAY 3401016</i> )	<b>Alport Syndrome</b> ( <i>ASSESS</i> )					<a href="#">NCT07211685</a>	Q3 2028	Study ongoing
<b>Dual FIIa/Xa Inhibitor</b> ( <i>BAY 3389934</i> )	<b>Sepsis-Induced Coagulopathy</b>					<a href="#">NCT06854640</a>	Q4 2026	Study ongoing
<b>GIRK4 Inhibitor</b> ( <i>BAY 3670549</i> )	<b>Atrial fibrillation</b>	Undisclosed				n/a	Q4 2025	Study completed
<b>BAY 3620122</b>	<b>Vasoplegia</b>					n/a	Q4 2026	Study ongoing

 Protein Therapy 
  Cell Therapy 
  Genetic Therapy 
  Radionuclide Therapy 
  Imaging Agent 
  Small Molecule

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit



# Pharmaceuticals – Pipeline Details Neurology & Rare Diseases<sup>1</sup>

(as of April 29, 2026)









Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status
<b>Bemdaneprocel</b> (Parkinson's Disease Cell Therapy)	<b>Parkinson's Disease</b> ( <i>exPDite-2</i> )					<a href="#">NCT06944522</a>	Q1 2027	Study ongoing
<b>Ametefgene Parvec</b> (AAV Gene Therapy) ( <i>AB-1005</i> )	<b>Parkinson's Disease</b> ( <i>REGENERATE-PD</i> )					<a href="#">NCT06285643</a>	Q3 2028	Study ongoing
	<b>Multiple System Atrophy</b>					<a href="#">NCT04680065</a>	Q3 2026	Study ongoing
<b>Pompe Disease AAV Gene Therapy</b> ( <i>AB-1009 aka PROGRESS-GT LOPD</i> )	<b>Pompe Disease</b>					<a href="#">NCT07282847</a>	Q3 2028	Study ongoing
<b>LGMD2I/R9 AAV Gene Therapy</b> ( <i>AB-1003 aka LION-101</i> )	<b>Limb-Girdle Muscular Dystrophy 2i</b>					<a href="#">NCT05230459</a>	Q4 2028	Study ongoing

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit



# Pharmaceuticals – Pipeline Details Others<sup>1</sup>

(as of April 29, 2026)

Candidate Medication	Indication	Modality	Phase I	Phase II	Phase III	Ct.gov Identifier	Estimated/Actual Primary Completion	Status	
<b>Mirena</b> (Levonorgestrel-releasing Intrauterine System)	<b>Endometrial Hyperplasia</b> ( <i>SUNFLOWER</i> )						<a href="https://clinicaltrials.gov/ct2/show/study/NCT06904274">NCT06904274</a>	<b>Q3 2027</b>	Study ongoing
<b>124I-Evuzamitide</b> (PET Tracer)	<b>Diagnosis of Cardiac Amyloidosis</b> ( <i>REVEAL</i> )						<a href="https://clinicaltrials.gov/ct2/show/study/NCT06788535">NCT06788535</a>	<b>Q1 2026</b>	Study completed
<b>Primary Photoreceptor Diseases Cell Therapy</b> ( <i>BRT-OpCT-001</i> )	<b>Primary Photoreceptor Disease</b>					<a href="https://clinicaltrials.gov/ct2/show/study/NCT06789445">NCT06789445</a>	<b>Q4 2029</b>	Study ongoing	
<b>AT-05 SPECT Tracer</b>	<b>Diagnosis of Cardiac Amyloidosis</b>					n/a	n/a	n/a	

<sup>1</sup> Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit